-
1 Comment
NuVasive, Inc is currently in a long term uptrend where the price is trading 13.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
NuVasive, Inc's total revenue sank by 6.0% to $292M since the same quarter in the previous year.
Its net income has dropped by 94.3% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.2% to $45M since the same quarter in the previous year.
Based on the above factors, NuVasive, Inc gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US6707041058 |
Sector | Healthcare |
Industry | Medical Devices |
Target Price | 45 |
---|---|
Market Cap | 2B |
PE Ratio | 75.0 |
Dividend Yield | 0.0% |
Beta | 1.07 |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NUVA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025